Ozempic, Wegovy, Mounjaro, Zepbound Associated With Loss of Eyesight
(Posted by Tom Lamb at Drug Injury Watch)
Non-arteritic anterior ischemic optic neuropathy (NAION) is a GLP-1 side effect that harms vision by causing damage to the eyes. In the past week, NAION news reports have put the spotlight on this relatively unknown drug safety issue for such popular drugs as Ozempic, Wegovy, Mounjaro, Zepbound, and others.
Here are a few of those recent NAION news reports:
“Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss” (Wall Street Journal, September 18, 2026)
“Are GLP-1s causing blindness? What we know about rare cases” (USA Today, September 21, 2026)
“Hundreds of lawsuits filed against some GLP-1 Makers over vision loss” (NBC Nightly News, September 21, 2026)
“What GLP-1 users should know about the potential risk of a rare type of vision loss” (ABC News, September 21, 2026)
NAION, Ozempic, and Wegovy Facts
Here is what you need to know to understand the significance of these NAION news reports about Ozempic and Wegovy being associated with loss of eyesight:
- Ozempic and Wegovy are drugs with semaglutide as their active ingredient.
- Semaglutide has been linked to nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is sometimes called an “eye stroke” because it develops when the optic nerve does not receive enough blood flow.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
- The current drug labels for Ozempic and Wegovy do not warn about eye-related side effects, such as possible vision loss.
__________________________________________________________________
Ozempic / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation.
__________________________________________________________________
NAION, Mounjaro, and Zepbound Facts
Here are some facts relevant to these NAION news reports about Mounjaro and Zepbound being associated with this drug side effect that harms vision:
- Nonarteritic anterior ischemic optic neuropathy (NAION) is characterized by loss of vision due to decreased blood flow to the optic nerve.
- Mounjaro (tirzepatide) is a newer and more potent GLP-1 drug intended to treat type 2 diabetes and obesity.
- Besides Mounjaro, there is a second GLP-1 drug that contains the active ingredient tirzepatide, Zepbound. That medication is used for obesity and weight loss purposes.
- There is some evidence that the NAION eye side effect may be associated with tirzepatide.
- The current drug labels for Mounjaro and Zepbound do not warn about NAION as a side effect associated with loss of eyesight.
__________________________________________________________________
Mounjaro / Zepbound
Free Case Evaluation
Strictly Confidential, No Obligation.
__________________________________________________________________
Before Recent NAION News Reports
We have been writing about this NAION GLP-1 side effect here on Drug Injury Watch since July 2024, starting with this article, “Wegovy, Rybelsus, and Ozempic Eye Side Effects: Semaglutide Linked to NAION“.
Just less than a month ago, we posted this article, “GLP-1 Lawsuits Involving NAION Filed in Federal Court: 200 Cases as of August 2026“.
And there are many more Drug Injury Watch articles written over the past couple of years regarding this NAION GLP-1 side effect, including several about medical studies showing Ozempic, Wegovy, Mounjaro, and Zepbound have been associated with loss of eyesight due to NAION.
Here are some past Drug Injury Watch articles from throughout this year, 2026, that predate and relate to these September 2026 news reports on NAION being linked to the GLP-1 drugs Ozempic, Wegovy, Mounjaro, and Zepbound.
Ozempic Eye Problems Side Effect Warnings Not In US Drug Label
Semaglutide-associated Vision Loss Due to NAION – New Medical Report, May 2026
Ozempic And Other GLP-1RA Use Associated With NAION Eye Side Effect
Wegovy and Ozempic Vision Loss: Wegovy Rate 5x Higher vs. Ozempic, Men 3x More Often vs. Women
While Rybelsus Pills Are Being Replaced With Pills Called Ozempic, Semaglutide NAION Risk Remains
Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs
NAION Eye Side Effect for Ozempic and Mounjaro: Drug Injury Lawsuits Update January 2026
Starting back in 2024, long before these recent NAION news reports, we have been investigating drug injury lawsuits for patients who have been diagnosed with this eye-related GLP-1 side effect that harms vision and can cause blindness in some cases.
Drug injury lawsuits involving Ozempic and Wegovy for patients with vision loss due to NAION would be filed against the responsible drug company, Novo Nordisk — which last week announced it was shortening its name to “Novo”.
Drug injury lawsuits involving Mounjaro or Zepbound for patients with vision loss due to NAION would be filed against Eli Lilly, the pharmaceutical company behind these two popular GLP-1 drugs.
These drug injury lawsuits seek legal compensation payments for the person suffering from a loss of vision or blindness due to NAION.
We offer an online case evaluation service that is free and confidential, and without obligation:
Ozempic / Wegovy Vision Loss Case Evaluation Form
Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form
Attorney Tom Lamb reviews these online submissions and will get back to you with his impressions. Or call 910-256-2971 to speak with him about your possible NAION eye side effect drug injury lawsuit.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects
Drug Injury Case Evaluation – Free. Confidential. No Obligation.